Axsome Therapeutics, Inc.

This Phase 3 trial is testing whether solriamfetol, a drug already approved for sleep disorders, can reduce binge eating episodes in adults with binge eating disorder. About 450 participants will receive either solriamfetol or a placebo daily for 12 weeks. The main goal is to see…

This study tests a drug called solriamfetol in adults with major depressive disorder who also struggle with excessive daytime sleepiness. About 508 participants will first receive the drug openly, then some will switch to a placebo to see if the drug helps prevent depressive symp…

This Phase 3 study tests whether AXS-14 (esreboxetine) can help manage fibromyalgia symptoms like pain and fatigue. About 620 adults with fibromyalgia will take the drug or a placebo daily. The study uses a 'randomized withdrawal' design to see how long the drug's effects last.

This Phase 3 trial tests whether the drug solriamfetol can reduce excessive sleepiness in people with shift work disorder. About 520 adults who work night shifts will take either solriamfetol or a placebo daily for 12 weeks. The study measures how well they stay awake and their o…